Provided legislative advocacy specific to the payment of innovative drugs, such as phosphate binders and anemia management drugs in the Medicare End-Stage Renal Dialysis Prospective Payment System (ESRD PPS).
2025 · 3rd Quarter (July 1 - Sep 30)
AKEBIA THERAPEUTICS, INC.
Filed by THE PETRIZZO GROUP, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 15, 2025
- Income
- $45,000.00
- Expenses
- Not reported
- Registrant
- THE PETRIZZO GROUP, INC.
- Filing UUID
- aa4c1af0-5a57-4acb-971d-adf29f60eef2
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Provided legislative advocacy specific to the payment of innovative drugs, such as phosphate binders and anemia management drugs in the Medicare End-Stage Renal Dialysis Prospective Payment System (ESRD PPS).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.